Sugi Predict

Sugi Predict / Compounds / SCHEMBL3350798

SCHEMBL3350798

SCHEMBL3350798

O=C(O)c1ccc(S(=O)(=O)N2CCCC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.72
▸ ALDH1A1 P00352 2/20 0.72
▸ NPC1 O15118 1/20 0.72
▸ RAB9A P51151 1/20 0.72
▸ SMN1; SMN2 Q16637 1/20 0.72
▸ USP2 O75604 1/20 0.68
▸ IL1RN P18510 1/20 0.66
▸ POLB P06746 1/20 0.65
▸ GLA P06280 1/20 0.64
▸ KDM4E B2RXH2 1/20 0.61
▸ LMNA P02545 1/20 0.61
▸ TP53 P04637 1/20 0.61
▸ GAA P10253 1/20 0.61
▸ KMT2A Q03164 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ TDP1 Q9NUW8 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26314073 0.98 USP2 (0.71) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL1832051 0.98 USP2 (0.71) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL28356029 0.96 MAPT (0.67) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL17303465 0.87 ALDH1A1 (0.74) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL18547806 0.86 MEN1 (0.57) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL1832768 0.84 L3MBTL1 (0.72) ALDH1A1SMN1; SMN2POLBLMNATP53
SCHEMBL29098532 0.84 ALDH1A1 (0.72) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL4911628 0.84 LMNA (0.77) ALDH1A1SMN1; SMN2USP2POLBLMNA
SCHEMBL25193214 0.84 MAPT (0.70) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL25196843 0.84 MAPT (0.70) MAPTALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 — — EP claimed
EP-3551634-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 — — EP claimed
CN-110099905-A SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-06 — — CN claimed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 — — CN claimed
WO-2018108231-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 — — WO claimed
EP-4257191-A2 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-10-11 — — EP disclosed
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 — — EP disclosed
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 — — EP disclosed
US-20220267306-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2022-08-25 — — US disclosed
US-11377439-B2 Heterocyclic prolinamide derivatives Orion Ophthalmology LLC (US) 2022-07-05 — — US disclosed
US-11377439-B2 Heterocyclic prolinamide derivatives Orion Ophthalmology LLC (US) 2022-07-05 — — US disclosed
CN-114685453-A Heterocyclic prolinamide derivatives 奥瑞恩眼科有限责任公司 2022-07-01 — — CN disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 — — US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 — — WO disclosed
WO-2010039982-A1 CRTH2 MODULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2010-04-08 — — WO disclosed
EP-0976722-B1 BENZAMIDINE DERIVATIVES AJINOMOTO KK (JP) 2009-03-11 — — EP disclosed
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders ASTRAZENECA AB (SE) 2008-10-16 — — US disclosed
US-7396844-B1 Benzamidine derivatives AJINOMOTO CO., INC. (JP) 2008-07-08 — — US disclosed
US-20050113450-A1 Antibacterial agents PHARMACIA & UPJOHN COMPANY 2005-05-26 — — US disclosed
WO-2004018414-A2 ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113450-A1 Antibacterial agents CLPP, SPOUT1, SAMHD1 MAPT 4753/4885ALDH1A1 462/4885NPC1 3512/4885
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR MAPT 1172/4885ALDH1A1 3391/4885NPC1 181/4885
US-20080255106-A1 Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders GSK3B, PYGB, GSK3A MAPT 7/4885ALDH1A1 3515/4885NPC1 1758/4885
US-20220267306-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, HTRA2 MAPT 3453/4885ALDH1A1 101/4885NPC1 2277/4885
US-11377439-B2 Heterocyclic prolinamide derivatives HTRA1, ALDH1A2, HTRA2 MAPT 3322/4885ALDH1A1 112/4885NPC1 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.